Early stage lung adenocarcinoma
Conditions
Interventions
Furmonertinib adjuvant therapy group:None
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old (based on age at the time of surgery); 2.Confirmed as non-small cell lung cancer (NSCLC) by histopathology or cytology, and having undergone radical surgical resection (R0 resection, meaning no residual tumor at the surgical margin); 3.According to the "AJCC Cancer Staging Manual (8th Edition)", the pathological stage is one of the following: Stage IA2 (pT1bN0M0) or Stage IA3 (pT1cN0M0) with at least one high-risk factor (see Criterion 4); Stage IB (pT2aN0M0); 4.For patients with stage IA2-IA3, they must have at least one of the following high-risk factors: 1) Pathologically poorly differentiated tumors (grade 3-4); 2) Presence of vascular invasion (Vascular Invasion); 3) Presence of lymphatic invasion (Lymphatic Invasion); 4) Histological subtype is micropapillary or predominantly solid adenocarcinoma; 5) Intrapulmonary airspace spread (STAS); 5.EGFR gene test indicates positive for sensitive mutations (such as Exon19del, L858R, etc.); 6.Received furmonertinib as adjuvant therapy after surgery; 7.At least one imaging follow-up should be completed after surgery, and the follow-up data should be accessible;
Exclusion criteria
Exclusion criteria: 1.The extent of surgical resection does not achieve R0 resection; 2.Patients with stage IA2-IA3 do not have any high-risk factors as defined in this protocol; 3.Key research data (such as EGFR mutation status, high-risk factors, medication information, etc.) are missing; 4.Concurrent adjuvant treatment with other EGFR-TKI drugs after surgery; 5.Complicated with severe underlying diseases or having a history of other malignant tumors;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-Free Survival (DFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Incidence and severity of adverse events (AE); | — |
Countries
China
Contacts
Public ContactQi Wanghong
The First Affiliated Hospital of Nanchang University
Outcome results
None listed